Click or
tap here
to read our
newsletter
  • Home
  • divider Collaboration

Collaboration makes us all better.

We believe in working side by side with researchers, healthcare professionals, patients, advocacy groups, and payers. By listening, learning, and sharing, we can deliver better solutions for patients and better value for all. By reaching out, we all reach higher.

Click or tap each circle to see the many ways we collaborate.

background
Delivering for biopharma

Fifteen of the top 20 pharmaceutical companies have relied on us to make their biologic medicines.6

Holding Office Hours

Our Office Hours program was created to open doors between scientists and entrepreneurs in early-stage initiatives.7

Listening to patients

We work with patient groups to deliver the medicines, education, and services that patients value the most.

Communicating with doctors

We participate in medical conferences and communities to stay current with physician concerns.

Working with researchers

We’re collaborating with the Sarah Cannon Research Institute, Yale University, and Vanderbilt University on cancer research.2-4

Delivering for biopharma Holding Office Hours Listening to patients Communicating with doctors Working with researchers
Delivering for biopharma Holding Office Hours Listening to patients Communicating with doctors Working with researchers
  • Working with researchers

    We’re collaborating with the Sarah Cannon Research Institute, Yale University, and Vanderbilt University on cancer research.2-4

  • Communicating with doctors

    We participate in medical conferences and communities to stay current with physician concerns.

  • Listening to patients

    We work with patient groups to deliver the medicines, education, and services that patients value the most.

  • Sharing molecules

    Our opnMe.com platform makes well-characterized molecules freely available to other scientists.5

  • Delivering for biopharma

    Fifteen of the top 20 pharmaceutical companies have relied on us to make their biologic medicines.6

  • Holding Office Hours

    Our Office Hours program was created to open doors between scientists and entrepreneurs in early-stage initiatives.7

Collaboration builds confidence.

We work with national authorities, healthcare systems, and payers to develop policies and programs that instill confidence and ensure continuity of care.

BBCIC

Boehringer Ingelheim is a founding participant of the Biologics and Biosimilars Collective Intelligence Consortium (BBCIC), a nonprofit organization.8

The BBCIC provides a single source of postapproval scientific data on safety and efficacy for biologics and biosimilars.8

To learn more about their many resources, go to:

www.bbcic.org
Biosimilars Forum

Boehringer Ingelheim is a founding member of the Biosimilars Forum, a group committed to expanding patient access to biologic medicines and providing doctors with timely, credible information about new treatment options.9,10

For educational materials, regulatory information, legislation, and more, go to our resources page:

www.biosimilarsforum.org
The Biosimilars Council

Boehringer Ingelheim participates in the Biosimilars Council, which provides a number of resources—reports, videos, news sources, and more—to educate the public and patients on biosimilar products.11,12 Go to:

www.biosimilarscouncil.org

We also participate in other trade associations, such as PhRMA, BIO, and the National Pharmaceutical Council.13-15

At Boehringer Ingelheim, we actively seek out partnerships to reach our ultimate goal: To provide innovative solutions for patients, physicians, and all stakeholders in the healthcare system.

New Treatments
New
Treatments16,17
  • Cancers (eg, lung, breast, colorectal)
  • Rheumatoid arthritis
  • Plaque psoriasis
  • Crohn's disease
  • Inflammatory bowel disease
  • Hepatitis C
  • Kidney disease
  • And more
New Hope
New
Hope
References:
  1. 1. Brainyquote.com website. https://www.brainyquote.com/quotes/claude_bernard_177952. Accessed July 10, 2018.
  2. 2. Business Wire website. Boehringer Ingelheim expands collaboration with Sarah Cannon Research Institute to investigate novel immuno-oncology combination therapy. https://www.businesswire.com/news/home/20171030005068/en/Boehringer-Ingelheim-expands-collaboration-Sarah-Cannon-Research. Published October 30, 2017. Accessed February 6, 2018.
  3. 3. Boehringer Ingelheim website. Press release. Boehringer Ingelheim and Yale University collaborate to investigate novel immunotherapy targets across several therapeutic areas. https://www.boehringer-ingelheim.com/press-release/boehringer-ingelheim-and-yale-university-collaborate-investigate-novel-immunotherapy. Accessed February 6, 2018.
  4. 4. Snyder B. Boehringer Ingelheim and Vanderbilt University expand partnership to develop novel treatment approaches for cancer. Vanderbilt University Medical Center website. http://news.vumc.org/2018/03/14/boehringer-ingeheim-and-vanderbilt-university-expand-partnership-to-develop-novel-treatment-approaches-for-cancer-home-stories/. Accessed July 11, 2018.
  5. 5. opnMe website. https://www.opnme.com. Accessed February 6, 2018.
  6. 6. Data on file. Ridgefield, CT: Boehringer Ingelheim Biopharmaceuticals, Inc.
  7. 7. Boehringer Ingelheim website. Supporting early-stage innovators. https://www.boehringer-ingelheim.com/partnering/engage/grass-roots. Accessed February 6, 2018.
  8. 8. Biologics and Biosimilars Collective Intelligence Consortium website. About the BBCIC. http://www.bbcic.org. Accessed February 6, 2018.
  9. 9. Biosimilars Forum website. About the Biosimilars Forum. http://www.biosimilarsforum.org/about-biosimilars-forum. Accessed February 6, 2018.
  10. 10. Biosimilars Forum website. Resources. http://www.biosimilarsforum.org/resources. Accessed July 12, 2018.
  11. 11. The Biosimilars Council website. About. https://biosimilarscouncil.org/about-us/. Accessed February 6, 2018.
  12. 12. The Biosimilars Council website. Home. https://biosimilarscouncil.org/. Accessed February 6, 2018.
  13. 13. Biotechnology Innovation Organization website. Member directory. https://www.bio.org/bio-member-directory/. Accessed July 11, 2018.
  14. 14. PhRMA, the Pharmaceutical Research and Manufacturers of America website. https://www.phrma.org/about/members. Accessed July 11, 2018.
  15. 15. National Pharmaceutical Council website. https://www.npcnow.org/about-npc/member-companies/. Accessed July 11, 2018.
  16. 16. Ryan AM. Frontiers in nonclinical drug development: biosimilars. Vet Pathol. 2015;52(2):419-426.
  17. 17. Bridges SL Jr, White DW, Worthing AB, et al. The science behind biosimilars: entering a new era of biologic therapy. Arthritis Rheumatol. 2018;70(3)334-344.